GlobeNewswire: Novelion Therapeutics, Inc. Contains the last 10 of 86 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:41:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/03/10/2624915/0/en/Novelion-Announces-Completion-of-Plan-of-Liquidation-and-Distribution-and-its-Voluntary-Dissolution.html?f=22&fvtc=4&fvtv=30771Novelion Announces Completion of Plan of Liquidation and Distribution and its Voluntary Dissolution2023-03-10T13:16:07Z<![CDATA[VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s liquidator (the “Liquidator”) today announced that Novelion has concluded the implementation of its plan of liquidation and distribution (the “Plan”) by winding down and dissolving the Company (the “Dissolution”).]]>https://www.globenewswire.com/news-release/2022/03/28/2411454/0/en/Novelion-Announces-Date-of-Final-Distribution-to-Registered-Shareholders.html?f=22&fvtc=4&fvtv=30771Novelion Announces Date of Final Distribution to Registered Shareholders2022-03-28T23:06:56Z<![CDATA[VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s liquidator (the “Liquidator”) today announced the anticipated date of its final cash distribution to its registered shareholders (the “Final Distribution”) will be on or about March 31, 2022.]]>https://www.globenewswire.com/news-release/2021/06/28/2254103/0/en/Novelion-Provides-Update-on-Final-Distribution-to-Registered-Shareholders.html?f=22&fvtc=4&fvtv=30771Novelion Provides Update on Final Distribution to Registered Shareholders2021-06-28T15:00:44Z<![CDATA[VANCOUVER, British Columbia, June 28, 2021 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s liquidator (the “Liquidator”) today provides an update in respect of its final distribution to its registered shareholders (the “Final Distribution”). The Company has determined that due to the interim distribution on March 11, 2021 of approximately 87.5% of the American depository receipts (“ADRs”) of Amryt Pharma plc (“Amryt”) held by the Company, the remaining ADRs will be monetized by the Company. It is expected that the Final Distribution will therefore be one distribution comprised of the cash remaining in Novelion, in addition to the proceeds from the sale of the remaining ADRs, less any expenses through the end of the Company’s statutory liquidation.]]>https://www.globenewswire.com/news-release/2021/03/04/2187562/0/en/Novelion-Announces-Date-of-Interim-Distribution-to-Registered-Shareholders.html?f=22&fvtc=4&fvtv=30771Novelion Announces Date of Interim Distribution to Registered Shareholders2021-03-04T20:35:21Z<![CDATA[VANCOUVER, British Columbia, March 04, 2021 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today announces that the previously announced interim distribution to its registered shareholders (the “Interim Distribution”) will take place on or about March 11, 2021. The Interim Distribution was approved pursuant to an Order of the Supreme Court of British Columbia (the “Court”) dated December 16, 2020 in accordance with the Company’s Plan of Liquidation and Distribution. By order dated February 24, 2021, the United States Bankruptcy Court for the Southern District of New York (US Court) granted recognition to the liquidation in the United States and confirmed that the Court Order with respect to the Interim Distribution is enforceable in the United States. The US Court further directed all entities in the United States to take any and all lawful action necessary to give effect to the Court Order and the transactions contemplated thereunder.]]>https://www.globenewswire.com/news-release/2021/01/26/2164645/0/en/Novelion-Provides-Update-on-Interim-Distribution-to-Registered-Shareholders.html?f=22&fvtc=4&fvtv=30771Novelion Provides Update on Interim Distribution to Registered Shareholders2021-01-26T19:49:35Z<![CDATA[VANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today announces that the timing of the previously announced interim distribution to its registered shareholders (the “Interim Distribution”) has been delayed. The delay of the Interim Distribution is due to the time required for the Company to undertake additional legal steps in the United States to effect the Interim Distribution. The Interim Distribution was approved pursuant to an Order of the Supreme Court of British Columbia (the “Court”) dated December 16, 2020 in accordance with the Company’s Plan of Liquidation and Distribution. Novelion will be taking steps in the United States to seek recognition and enforcement of the approvals and authorizations in such Court Order.]]>https://www.globenewswire.com/news-release/2020/12/23/2150282/0/en/Novelion-Announces-Court-Approval-for-Interim-Distribution-to-Registered-Shareholders.html?f=22&fvtc=4&fvtv=30771Novelion Announces Court Approval for Interim Distribution to Registered Shareholders2020-12-23T22:00:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today announces its intention to make an interim distribution to its registered shareholders in January 2021 (the “Interim Distribution”). The Interim Distribution will be made pursuant to an Order of the Supreme Court of British Columbia (the “Court”) dated December 16, 2020 in accordance with the Company’s Liquidation Plan. The mechanics of the Interim Distribution are in the process of being finalized and the date of the Interim Distribution will be communicated to the Company’s shareholders by way of a subsequent press release once confirmed.]]>https://www.globenewswire.com/news-release/2020/09/30/2101662/0/en/Novelion-Therapeutics-Provides-Update-on-Liquidation-Process.html?f=22&fvtc=4&fvtv=30771Novelion Therapeutics Provides Update on Liquidation Process2020-09-30T18:06:53Z<![CDATA[VANCOUVER, British Columbia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today provides an update on the Company’s voluntary liquidation process (the “Liquidation”) that started on January 16, 2020 (the “Effective Date”).]]>https://www.globenewswire.com/news-release/2020/07/08/2059540/0/en/Novelion-Therapeutics-Ceases-to-be-a-Reporting-Issuer-in-Canada.html?f=22&fvtc=4&fvtv=30771Novelion Therapeutics Ceases to be a Reporting Issuer in Canada2020-07-08T19:17:00Z<![CDATA[VANCOUVER, British Columbia, July 08, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) announces that it has ceased to be a reporting issuer under Canadian securities legislation in each of the provinces of Canada as a result of an order issued by the British Columbia Securities Commission on behalf of itself and other Canadian securities regulatory authorities. The order was issued in response to an application made by Novelion and accordingly, Novelion will no longer be required to file financial statements or other continuous disclosure documents with Canadian securities regulatory authorities.]]>https://www.globenewswire.com/news-release/2020/06/12/2047598/0/en/Novelion-Therapeutics-Provides-Update-on-Liquidation-and-Claims-Process.html?f=22&fvtc=4&fvtv=30771Novelion Therapeutics Provides Update on Liquidation and Claims Process2020-06-12T17:38:53Z<![CDATA[VANCOUVER, British Columbia, June 12, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today provides an update on the Company’s voluntary liquidation process (the “Liquidation”) that started on January 16, 2020 (the “Effective Date”).]]>https://www.globenewswire.com/news-release/2020/01/17/1971805/0/en/Novelion-Therapeutics-Confirms-Commencement-of-Voluntary-Liquidation.html?f=22&fvtc=4&fvtv=30771Novelion Therapeutics Confirms Commencement of Voluntary Liquidation2020-01-17T01:05:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) today announced that the implementation of the Company’s voluntary liquidation (the “Liquidation”) commenced at 5:00 p.m. Pacific Time today, January 16, 2020 (the “Effective Date”).]]>